Table 2.

Cell viability % of MCF-10 A cells upon treatment with 50 µM of compounds 7a-x for 96 h and IC50 of compounds 7a-x & Doxorubicin in A-549, MCF-7, Panc-1 and HT-29 after 48 h incubation

Compound	Cell viability % in MCF-10 A (50 µM)	IC50 ± SEM (µM)
		A-549	MCF-7	Panc-1	HT-29
7a	91	9.90 ± 1.10	9.20 ± 1.10	10.40 ± 1.30	11.15 ± 1.40
7b	88	8.20 ± 0.90	7.90 ± 0.80	8.40 ± 1.00	9.10 ± 1.10
7c	87	4.70 ± 0.50	4.15 ± 0.50	5.20 ± 0.40	5.50 ± 0.50
7d	89	9.70 ± 1.10	8.90 ± 1.10	10.30 ± 1.30	11.10 ± 1.40
7e	87	1.60 ± 0.30	1.25 ± 0.08	1.70 ± 0.30	1.95 ± 0.30
7f	87	2.15 ± 0.50	2.05 ± 0.50	2.40 ± 0.60	2.70 ± 0.50
7g	91	1.80 ± 0.60	1.45 ± 0.30	1.90 ± 0.50	2.10 ± 0.60
h	87	1.95 ± 0.60	1.75 ± 0.40	2.05 ± 0.50	2.25 ± 0.60
7i	84	9.70 ± 1.10	9.20 ± 1.00	10.15 ± 1.20	10.20 ± 1.30
7j	89	9.95 ± 1.10	9.40 ± 1.20	10.30 ± 1.20	10.70 ± 1.10
7k	91	1.20 ± 0.20	0.95 ± 0.08	1.30 ± 0.20	1.40 ± 0.20
7l	89	1.45 ± 0.30	1.10 ± 0.10	1.50 ± 0.30	1.65 ± 0.30
7m	94	1.40 ± 0.50	1.20 ± 0.08	1.50 ± 0.20	1.85 ± 0.40
7n	92	1.90 ± 0.60	1.65 ± 0.30	2.05 ± 0.50	2.20 ± 0.60
7o	89	7.60 ± 0.30	7.10 ± 0.60	8.20 ± 1.20	8.60 ± 0.40
7p	87	2.50 ± 0.50	2.10 ± 0.20	3.10 ± 0.40	3.30 ± 0.40
7q	94	3.40 ± 0.40	3.02 ± 0.30	3.80 ± 0.50	3.70 ± 0.50
7r	91	3.60 ± 0.50	3.10 ± 0.50	3.90 ± 0.50	4.20 ± 0.50
7s	87	3.80 ± 0.60	3.15 ± 0.50	4.30 ± 0.60	4.55 ± 0.60
7t	88	10.60 ± 1.10	10.10 ± 1.00	10.90 ± 1.20	10.80 ± 1.20
7u	90	2.25 ± 0.50	2.10 ± 0.08	2.40 ± 0.20	2.70 ± 0.50
7v	87	2.45 ± 0.50	2.20 ± 0.08	2.60 ± 0.20	2.90 ± 0.50
7w	91	10.90 ± 1.10	10.20 ± 1.20	11.15 ± 1.20	11.20 ± 1.30
7x	85	11.50 ± 1.20	10.800 ± 1.10	11.80 ± 1.20	12.50 ± 1.50
Doxorubicin	-	1.21 ± 0.10	0.90 ± 0.10	1.41 ± 0.10	1.01 ± 0.10